Stereochemistry | ABSOLUTE |
Molecular Formula | C14H16O3 |
Molecular Weight | 232.275 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=O)O[C@@H](CCC2=CC=CC=C2)C1
InChI
InChIKey=VOOYTQRREPYRIW-LBPRGKRZSA-N
InChI=1S/C14H16O3/c1-16-13-9-12(17-14(15)10-13)8-7-11-5-3-2-4-6-11/h2-6,10,12H,7-9H2,1H3/t12-/m0/s1
Molecular Formula | C14H16O3 |
Molecular Weight | 232.275 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Sample Use Guides
Pretreatment with dihydrokavain (300 uM) significantly decreased the nucleus tractus solitarius (NTS) inhibitory effects induced by muscimol (30 uM), approximately from 51 % to 36 %. Dihydrokavain induced inhibitory effects was not reduced after co-application of saclofen or naloxone.